HLA alleles associated to susceptibility to gliptin-associated bullous pemphigoid in Italian patients.
HLA‐DQB1*03:01
bullous pemphigoid
gliptin
Journal
HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
revised:
25
06
2024
received:
19
04
2024
accepted:
15
07
2024
medline:
2
8
2024
pubmed:
2
8
2024
entrez:
2
8
2024
Statut:
ppublish
Résumé
Bullous pemphigoid (BP), although a rare disease, is the most frequent subepidermal autoimmune disorder. Treatment with gliptins, used for type 2 diabetes, was reported as associated with BP onset. To identify HLA alleles that may reflect a higher susceptibility to BP in the Italian population, we analysed 30 patients affected by idiopathic bullous pemphigoid (IBP) and 86 gliptin-associated BP (GABP) patients. A significant association between HLA-DQB1*03:01 allele and IBP and GABP patients was found. Of note, both IBP and GABP were significantly associated with one of the following haplotypes: DRB1*11:01, DRB3*02:02, DQA1*05:05, DQB1*03:01 or DRB1*11:04, DRB3*02:02, DQA1*05:05 and DQB1*03:01. These data identify, for the first time, potential markers of susceptibility to BP in the Italian population, especially when associated with gliptin intake.
Substances chimiques
HLA-DQB1 antigen
0
HLA-DQ beta-Chains
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15616Subventions
Organisme : Italian Ministry of Health
ID : RF-2018-12367807
Informations de copyright
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Genovese G, Di Zenzo G, Cozzani E, Berti E, Cugno M, Marzano AV. New insights into the pathogenesis of bullous pemphigoid: 2019 update. Front Immunol. 2019;10:1506. doi:10.3389/fimmu.2019.01506
Moro F, Fania L, Sinagra JLM, Salemme A, Di Zenzo G. Bullous pemphigoid: trigger and predisposing factors. Biomolecules. 2020;10:1432. doi:10.3390/biom10101432
Merli M, Accorinti M, Romagnuolo M, et al. Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience. Front Med (Lausanne). 2023;10:1208418. doi:10.3389/fmed.2023.1208418
Salemme A, Fania L, Scarabello A, et al. Gliptin‐associated bullous pemphigoid shows peculiar features of anti‐BP180 and ‐BP230 humoral response: results of a multicenter study. J Am Acad Dermatol. 2022;87:56‐63. doi:10.1016/j.jaad.2022.02.036
Lindgren O, Varpuluoma O, Tuusa J, et al. Gliptin‐associated bullous pemphigoid and the expression of dipeptidyl peptidase‐4/CD26 in bullous pemphigoid. Acta Derm Venereol. 2019;99:602‐609. doi:10.2340/00015555‐3166
Delgado JC, Turbay D, Yunis EJ, et al. A common major histocompatibility complex class II allele HLA‐DQB1*0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci U S A. 1996;93:8569‐8571. doi:10.1073/pnas.93.16.8569
Banfield CC, Wojnarowska F, Allen J, George S, Venning VA, Welsh KI. The association of HLA‐DQ7 with bullous pemphigoid is restricted to men. Br J Dermatol. 1998;138:1085‐1090. doi:10.1046/j.1365‐2133.1998.02350.x
Büdinger L, Borradori L, Yee C, et al. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest. 1998;102:2082‐2089. doi:10.1172/JCI3335
Esmaili N, Mortazavi H, Chams‐Davatchi C, et al. Association between HLA‐DQB1*03:01 and bullous pemphigoid in Iranian patients. Iran J Immunol. 2013;10:1‐9.
Chagury AA, Sennes LU, Gil JM, et al. HLAC*17, DQB1*03:01, DQA1*01:03 and DQA1*05:05 alleles associated to bullous pemphigoid in Brazilian population. Ann Dermatol. 2018;30:8‐12. doi:10.5021/ad.2018.30.1.8
Fang H, Shen S, Zheng X, et al. Association of HLA class I and class II alleles with bullous pemphigoid in Chinese Hans. J Dermatol Sci. 2018;89:258‐262. doi:10.1016/j.jdermsci.2017.11.014
Sun Y, Liu H, Wang Z, et al. The HLA‐DQB1*03:01 is associated with bullous pemphigoid in the Han Chinese population. J Invest Dermatol. 2018;138:1874‐1877. doi:10.1016/j.jid.2018.02.021
Okazaki A, Miyagawa S, Yamashina Y, Kitamura W, Shirai T. Polymorphisms of HLA‐DR and ‐DQ genes in Japanese patients with bullous pemphigoid. J Dermatol. 2000;27:149‐156. doi:10.1111/j.1346‐8138.2000.tb02141.x
Gao X‐H, Winsey S, Li G, et al. HLA‐DR and DQ polymorphisms in bullous pemphigoid from northern China. Clin Exp Dermatol. 2002;27:319‐321. doi:10.1046/j.1365‐2230.2002.01037.x
Schwarm C, Gola D, Holtsche MM, et al. Identification of two novel bullous pemphigoid—Associated alleles, HLA‐DQA1*05:05 and ‐DRB1*07:01, in Germans. Orphanet J Rare Dis. 2021;16:228. doi:10.1186/s13023‐021‐01863‐9
Hesari R, Thibaut D, Schur N, Thoutireddy S, Witcher R, Julian E. Bullous pemphigoid and human leukocyte antigen (HLA)‐DQA1: a systematic review. Cureus. 2023;15:e39923. doi:10.7759/cureus.39923
Ujiie H, Muramatsu K, Mushiroda T, et al. HLA‐DQB1*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP‐4 inhibitors. J Invest Dermatol. 2018;138:1201‐1204. doi:10.1016/j.jid.2017.11.023
Ozeki T, Muramatsu K, Yoshimoto N, et al. Association of genetic variants of HLA‐DQA1 with bullous pemphigoid induced by dipeptidyl peptidase‐4 inhibitors. J Invest Dermatol. 2023;143:2219‐2225. doi:10.1016/j.jid.2023.04.017